PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Recruiting now · Phase 1

Conditions studied: Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA

In brief

This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. Diagnostic procedures, such as PET/MRI, 18F-FDG PET/CT and whole body MRI, may help find and diagnose extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.

Key facts

Study ID

NCT02390635

Run by

M.D. Anderson Cancer Center

People needed

77

Starts

2020-07-15

Expected to finish

2027-09-15

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with newly diagnosed AML
• Non-English speaking subjects will be included. Verbal Translation Preparative Sheet (VTPS) short form will be utilized in consenting non-English speaking subjects.

You may not qualify if…

• Patients with contraindications to MR
• Patients with a known allergy to MR contrast agents
• Uncontrollable claustrophobia
• Recipients of more than minimal anti-leukemia treatment, with minimal treatment defined as: leukapheresis, hydroxyurea, or Cytarabine more than 1 g per square meter.
• Patients with secondary or relapsed AML or APL should be excluded.
• Patients with known extramedullary leukemia
• Positive pregnancy test in a female of childbearing potential
• Younger than 18 years
• Greater than 400 pounds in weight
• Patients with uncontrolled diabetes
• Cognitive impaired adults or prisoners will be excluded
• Estimated glomerular filtration rate (eGFR <30) will be excluded

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.